EMA accepts Teva application for long-acting olanzapine schizophrenia drug
The European Medicines Agency has accepted Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) marketing authorization application for TEV-'749, a long-acting injectable ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)